Loading
A phase 1 trial of Micvotabart pelidotin run by Pyxis Oncology, Inc, now recruiting.
A Study of PYX-201 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT05720117 by Pyxis Oncology, Inc, with 330 participants planned, started 2023-03-14, primary completion expected 2027-04-25. Conditions recorded: Solid Tumor, Advanced Solid Tumor. Interventions recorded: PYX-201.
Shares Micvotabart pelidotin, Pyxis Oncology and the tag pipeline.
Shares Micvotabart pelidotin, Pyxis Oncology.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/